- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — Young people with type 2 ...
Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned insulin ...
INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial ...
Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback